scholarly journals Role of cytochrome P450 2C8 genetic polymorphism and epoxygenase uncoupling in periodontal remodeling affecting orthodontic treatment

2021 ◽  
Author(s):  
Sabrina Yamoune ◽  
Katharina Wintz ◽  
Christian Niederau ◽  
Rogerio B. Craveiro ◽  
Michael Wolf ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Orthodontic Treatment ◽  
Cytochrome P450 2C8

The Role of Ile476 in the Structural Stability and Substrate Binding of Human Cytochrome P450 2C8

2009 ◽  
Vol 29 (1) ◽  
pp. 32-43 ◽  
Author(s):  
Lu Sun ◽  
Zhong-Hua Wang ◽  
Feng-Yun Ni ◽  
Xiang-Shi Tan ◽  
Zhong-Xian Huang
Keyword(s):  
Cytochrome P450 ◽  
Structural Stability ◽  
Substrate Binding ◽  
Cytochrome P450 2C8 ◽  
Human Cytochrome

scholarly journals Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease

2008 ◽  
Vol 18 (11) ◽  
pp. 943-953 ◽  
Author(s):  
Helen E. Smith ◽  
J.P. Jones ◽  
Thomas F. Kalhorn ◽  
Federico M. Farin ◽  
Patricia L. Stapleton ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Cytochrome P450 ◽  
Kidney Disease ◽  
Calcineurin Inhibitor ◽  
Cytochrome P450 2C8

scholarly journals Breast cancer: Role of pharmacogenetics in tamoxifen therapy

2016 ◽  
Vol 1 (1) ◽  
pp. 10
Author(s):  
Smriti Mishra ◽  
Manish Manish
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Clinical Outcome ◽  
Tamoxifen Therapy ◽  
Uridine Diphosphate ◽  
Cytochrome P450 2D6 ◽  
Cytochrome P450 3A ◽  
P450 2D6

<p><span>The role of pharmacogenetics in the personalization of tamoxifen therapy has relevance in the management of breast cancer. Since Tamoxifen is a pro-drug, genetic polymorphism in Phase I and Phase II drug metabolizing enzymes involved in the bioconversion of tamoxifen to therapeutically active metabolites is critical in determining therapeutic efficacy and adverse drug reactions of the therapy in breast cancer patients. In this review, the role of pharmacogenetics in the personalization of tamoxifen therapy has been discussed. Since, metabolism of tamoxifen by Cytochrome P450 2D6 is significant in determining the therapeutic efficacy of the drug, most of the clinical evidence on tamoxifen pharmacogenetics have been correlated with cytochrome p450 2D6 genetic polymorphism. However, there is discordance in the clinical data, and one of the reasons is the incomplete analysis of all the alleles of cytochrome p450 2D6. International Tamoxifen Pharmacogenomics Consortium has been formed to assess   the discordance. There are also clinical evidences associating genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome of tamoxifen therapy. However, associations of genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome in populations of different ethnicity are unexplored. Evidences on  the association of genetic polymorphisms and the clinical outcome have been summarized in the Table.  Since cost, statistically significant sample population size, labor and ethical issues are the major concerns of a pharmacogenetic investigation; the significance of bottom-up approach in pharmacogenetics has been discussed.</span></p>

scholarly journals Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro

2016 ◽  
pp. 1909 ◽  
Author(s):  
Zhe Wang ◽  
Li Wang ◽  
Ren-ai Xu ◽  
Yun-yun Zhan ◽  
Cheng-ke Huang ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

The role of genetic polymorphism of cytochrome P450 family member in schizophrenia

2019 ◽  
Vol 29 ◽  
pp. S454-S455
Author(s):  
R. Zakharyan ◽  
V. Hayrapetyan ◽  
L. Karapetyan ◽  
A. Chavushyan ◽  
A. Arakelyan
Keyword(s):  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Family Member ◽  
Cytochrome P450 Family

scholarly journals Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

2015 ◽  
Vol 68 (1) ◽  
pp. 168-241 ◽  
Author(s):  
Janne T. Backman ◽  
Anne M. Filppula ◽  
Mikko Niemi ◽  
Pertti J. Neuvonen
Keyword(s):  
Cytochrome P450 ◽  
Drug Metabolism ◽  
Cytochrome P450 2C8

Pharmacogenetics of Clozapine: In Vivo Role of Cytochrome P450 Isoforms and P-Glycoprotein

2008 ◽  
Vol 41 (05) ◽  
Author(s):  
E Jaquenoud-Sirot ◽  
B Knezevic ◽  
G Perla Morena ◽  
P Baumann ◽  
CB Eap
Keyword(s):  
Cytochrome P450 ◽  
P Glycoprotein ◽  
Cytochrome P450 Isoforms

Association of genetic polymorphism of cytokines and antioxidant enzymes with the development of asbestosis

2020 ◽  
Vol 60 (12) ◽  
pp. 898-903
Author(s):  
Lyudmila P. Kuzmina ◽  
Anastasiya G. Khotuleva ◽  
Evgeniy V. Kovalevsky ◽  
Nikolay N. Anokhin ◽  
Iraklij M. Tskhomariya
Keyword(s):  
Antioxidant Enzymes ◽  
Genetic Polymorphism ◽  
Genetic Predisposition ◽  
Risk Groups ◽  
Dust Exposure ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Gstp1 Gene ◽  
Polymorphic Variants

Introduction. Various industries widely use chrysotile asbestos, which determines the relevance of research aimed at the prevention of asbestos-related diseases. It is promising to assess the role of specific genes, which products are potentially involved in the development and regulation of certain links in the pathogenesis of asbestosis, forming a genetic predisposition to the disease. The study aims to analyze the presence of associations of genetic polymorphism of cytokines and antioxidant enzymes with asbestosis development. Materials and methods. Groups were formed for examination among employees of OJSC "Uralasbest" with an established diagnosis of asbestosis and without lung diseases. For each person included in the study, dust exposure doses were calculated considering the percentage of time spent at the workplace during the shift for the entire work time. Genotyping of single nucleotide polymorphisms of cytokines IL1b (rs16944), IL4 (rs2243250), IL6 (rs1800795), TNFα (rs1800629) and antioxidant enzymes SOD2 (rs4880), GSTP1 (rs1610011), CAT (rs1001179) was carried out. Results. The authors revealed the associations of polymorphic variants A511G IL1b gene (OR=2.457, 95% CI=1.232-4.899) and C47T SOD2 gene (OR=1.705, 95% CI=1.055-2.756) with the development of asbestosis. There was an increase in the T allele IL4 gene (C589T) frequency in persons with asbestosis at lower values of dust exposure doses (OR=2.185, 95% CI=1.057-4.514). The study showed the associations of polymorphism C589T IL4 gene and C174G IL6 gene with more severe asbestosis, polymorphism A313G GSTP1 gene with pleural lesions in asbestosis. Conclusion. Polymorphic variants of the genes of cytokines and antioxidant enzymes, the protein products directly involved in the pathogenetic mechanisms of the formation of asbestosis, contribute to forming a genetic predisposition to the development and severe course of asbestosis. Using the identified genetic markers to identify risk groups for the development and intense period of asbestos-related pathology will optimize treatment and preventive measures, considering the organism's characteristics.

Sign in / Sign up

Export Citation Format

Share Document